Mr Ian NOBLE is a trained Health Economist with over 20 years experience working in market access roles in traditional pharmaceutical companies, biotechnology companies and in consultancy roles in the UK, Switzerland and Australia. In 2013 he set up Noble Pharma Consulting to provide consulting services to stakeholders in the Biopharmaceutical sector.
Since 1999, he has engaged within the Australian system to achieve access for medicines to the Pharmaceutical Benefits Scheme (PBS) for Amgen and Merck Sharpe & Dohme. Over this period he has also worked closely with the innovative industry association, Medicines Australia and the Department of Health to help shape health technology assessment and payer policy as a member of the Access to Medicines Working Group (2008–2013), PBAC Guidelines Working Group (2007–2013) and Health Economics Working Group (2001–2010). Ian holds degrees in Economics (BSc) and Health Economics (MSc).